Haleon (LSE:HLN) is back on investor watchlists after fresh returns data showed the shares down about 4% over the past month and roughly 4% over the past 3 months. That shorter term weakness sits against a tougher backdrop, with Haleon’s share price return down 7.8% year to date and the 1 year total shareholder return slipping 7.5%, even though the 3 year total shareholder return remains positive at about 10%. Scan how Haleon compares to other defensive healthcare plays under pressure by...
Haleon has delivered a 10.0% share price gain over the past three years, yet the stock is still asking investors to judge whether that journey lines up with the cash it is expected to generate. The open question is whether the current valuation of Haleon stock can be explained by the stream of cash flows implied in its price today. That 10.0% return over three years puts real money on the line for anyone asking whether Haleon's current share price can be backed by the cash it is expected to...
Haleon has underperformed since its 2022 spin from GSK, delivering just over 6% annualized returns, including dividends. Read why HLN stock is a Buy.
Haleon has started a share repurchase programme authorised at its April 2026 AGM, allowing buybacks of up to 890,000,000 shares, or about 10% of issued capital, with flexibility to hold shares in treasury, use them for incentives or cancel them before the authority expires in mid 2027. The business now expects organic sales growth around 2.5% for the year and faces a regulatory suspension of Centrum production and sales in China, which is projected to reduce 2027 operating profit by about...
Haleon PLC (LSE:HLN, NYSE:HLN) received a Deutsche Bank upgrade despite a target cut, while RBC lowered its target and JPMorgan remained cautious after the group's third-quarter miss and guidance warning. Deutsche Bank moved from 'sell' to 'hold', RBC retained 'sector perform', and JPMorgan...
London's FTSE 100 closed 0.29% higher on Thursday as investors digested new economic updates and ear
Oct 29 (Reuters) - Haleon cut its sales outlook to below market forecasts on Thursday, hurt by weak demand for flu and cold medicines and a regulatory setback in China, sparking the biggest-ever one-day fall in the British consumer health group's shares. The stock, spun off from drugmaker GSK in July 2022, was down nearly 15% by 1300 GMT, making it the worst performer in European and British benchmark indexes.
Haleon (LSE:HLN) lowered its full-year organic revenue growth forecast on Thursday following third-quarter trading that fell below company expectations, while announcing an additional £500 million share repurchase programme. Shares in the consumer healthcare group declined approximately 12.
Performance was held back by weaker sales in cough, cold and flu products, particularly with lower orders in North America.
The FTSE 100 company said revenues grew by 2.5% to £2.87 billion for the three months to September 30, compared with the same period last year.
Detailed price information for Haleon Plc (HLN-N) from The Globe and Mail including charting and trades.
Detailed price information for Haleon Plc (HLN-N) from The Globe and Mail including charting and trades.
Unilever PLC (LSE:ULVR) is on JP Morgan's 'positive watch', and Haleon PLC (LSE:HLN, NYSE:HLN) on 'negative watch', ahead of third-quarter reporting by European consumer staples companies. The note adds Givaudan to positive watch alongside Unilever, Heineken N.V. (AEX:HEIA) and Danone...
This is the newest page. Registered accounts read further back.